A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial
SI Ou, M Koczywas, S Ulahannan, P Janne… - Journal of Thoracic …, 2020 - jto.org
Background: Mutations in KRAS are among the most common aberrations in cancer.
However, despite considerable research efforts, KRAS remains a challenging therapeutic …
However, despite considerable research efforts, KRAS remains a challenging therapeutic …
[PDF][PDF] The SHP2 inhibitor RMC-4630 in Patients with KRAS-mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial
SI Ou, M Koczywas, S Ulahannan, P Janne… - … - rvmdpubs.revmed.com.s3 …
• RAS signaling is frequently dysregulated in human cancers• Treatment options are limited
for patients with tumors harboring RAS, NF1, or BRAF mutations other than BRAFV600E• …
for patients with tumors harboring RAS, NF1, or BRAF mutations other than BRAFV600E• …